<DOC>
	<DOCNO>NCT02092285</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy golimumab maintain clinical response participant moderate-to-severe ulcerative colitis .</brief_summary>
	<brief_title>Golimumab Utilization Impact Ulcerative Colitis ( MK-8259-032 )</brief_title>
	<detailed_description>This study consist 1 week screening period , 54 week treatment period , 12 week follow-up period , require total 7 trial site visit : Visit 1 ( screen visit , Week -1 ) , Visit 2 ( enrollment visit , Day 0 ) , Visit 3 ( Week 2 ) , Visit 4 ( Week 6 ) , Visit 5 ( Week 30 ) Visit 6 ( Week 54 ) Visit 7 ( follow-up visit , Week 66 ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis ulcerative colitis least 3 month moderatetosevere disease enrollment . Has rectal bleeding subscore 1 baseline . No evidence active , latent , inadequately treated infection Mycobacterium tuberculosis ( TB ) . Must eligible start golimumab treatment accord summary product characteristic . Must na√Øve antitumor necrosis factor ( antiTNF ) therapy . Women childbearing potential men capable father child must agree use adequate birth control measure ( eg , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , implant , surgical sterilization ) . Women childbearing potential must test negative pregnancy screen . Any prior azathioprine / 6mercaptopurine use initiate least 12 week prior enrollment either stable dose discontinue treatment 4 week immediately prior enrollment . Clinical sign ischaemic colitis , fulminant colitis toxic megacolon . Has evidence pathogenic bowel infection . Has diagnosis indeterminate colitis , clinical finding suggestive Crohn 's disease . Has surgery treatment ulcerative colitis , likely require surgery . Has ulcerative colitis confine proctitis ( distal 15 cm less ) . Has current recent history severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , metabolic , endocrine , pulmonary , cardiac , neurological disease . Has current immunization live virus vaccine history immunization live virus vaccine within 3 month baseline . Pregnant lactating , plan pregnancy enrol study . Has receive agent deplete B T cell ( eg , rituximab alemtuzumab ) within 12 month prior study inclusion , continue manifest depletion B T cell 12 month completion therapy lymphocytedepleting agent . Has receive cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil ( MMF ) within 8 week prior study inclusion . Has use investigational drug within 30 day Screening . Has know hypersensitivity human immunoglobulin proteins component golimumab . Has receive methotrexate within 12 week prior enrollment Has receive rectal corticosteroid rectal 5aminosalicylic acid ( 5ASA ) compound within 2 week prior enrollment ( may commence require Week 6 study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>